Nebivolol Krka

Nebivolol, the active ingredient in Nebivolol Krka, is a selective β1‑adrenergic antagonist (beta‑blocker) presented as an oral tablet for oral administration. It is used to lower high blood pressure and to improve outcomes in patients with chronic heart failure, acting primarily in adult populations. Nebivolol reduces heart rate and peripheral vascular resistance through β1‑blockade combined with nitric‑oxide mediated vasodilation, providing a dual mechanism that supports cardiovascular control.

GNH USA supplies Nebivolol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular conditions.

- Hypertension: lowers systolic and diastolic blood pressure in adult patients. - Heart failure: improves left‑ventricular function and reduces risk of hospitalization. - Left ventricular dysfunction: enhances cardiac output and symptom control in patients with reduced ejection fraction.

Nebivolol may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: especially when standing up quickly. - Bradycardia: slower than normal heart rate. - Nausea: upset stomach or feeling of queasiness. - Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: heart rate dropping to dangerously low levels. - Hypotension: significant drop in blood pressure causing faintness. - Bronchospasm: narrowing of airways, particularly in patients with asthma. - Heart block: impairment of electrical conduction in the heart. - Allergic reactions: rash, itching, or swelling of face and throat. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating Nebivolol, clinicians should consider several safety measures.

- Monitor heart rate: ensure baseline rate is appropriate before dosing. - Assess blood pressure: check for hypotension risk, especially in volume‑depleted patients. - Use caution in asthma/COPD: β‑blockade may exacerbate bronchospasm. - Avoid abrupt discontinuation: taper to prevent rebound hypertension. - Adjust dose in renal impairment: reduced clearance may require lower dosing. - Store at room temperature: keep in the original pack, protect from moisture.

Nebivolol can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Combined with other β‑blockers: risk of excessive bradycardia and hypotension. - With non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): may cause severe conduction delays. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): increase nebivolol plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: may amplify blood‑pressure lowering effect. - ACE inhibitors or ARBs: additive hypotensive effect. - Anti‑arrhythmic agents (e.g., amiodarone): may affect cardiac rhythm.